PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.96%
Revenue growth of 4.96% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
8.17%
Gross profit growth of 8.17% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
24.49%
Positive EBIT growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong competitive advantage in operations.
28.69%
Positive operating income growth while Medical - Pharmaceuticals is negative. Peter Lynch would spot a big relative advantage here.
-17.71%
Negative net income growth while Medical - Pharmaceuticals median is -4.46%. Seth Klarman would investigate factors dragging net income down.
-17.71%
Negative EPS growth while Medical - Pharmaceuticals median is -0.86%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-17.71%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.00%
Share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.03%. Joel Greenblatt would applaud significant buybacks if they are value-accretive.
0.00%
Diluted share growth above 2x Medical - Pharmaceuticals median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
34.57%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 7.29%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
-15.64%
Negative 5Y CAGR while Medical - Pharmaceuticals median is 3.74%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
32.43%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 8.45%. Joel Greenblatt might see a short-term competitive advantage at play.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
71.27%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 40.40% over a decade. Joel Greenblatt might see a standout compounder of earnings.
-21.87%
Negative 5Y CAGR while Medical - Pharmaceuticals median is 9.06%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
70.89%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 21.59%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
No Data
No Data available this quarter, please select a different quarter.
24.39%
5Y equity/share CAGR 1.25-1.5x Medical - Pharmaceuticals median. Mohnish Pabrai might see disciplined retention of earnings behind outperformance.
70.99%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 28.27%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
-100.00%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.55%
AR growth of 4.55% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
0.14%
Inventory growth of 0.14% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
2.08%
Asset growth of 2.08% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
4.03%
BV/share growth of 4.03% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-30.60%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
94.28%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.